Chang Anne B, Clark Ronald, Sloots Theo P, Stone David G, Petsky Helen L, Thearle Donna, Champion Anita A, Wheeler Coralie, Acworth Jason P
Royal Children's Hospital, Brisbane, QLD, Australia.
Med J Aust. 2008 Sep 15;189(6):306-10. doi: 10.5694/j.1326-5377.2008.tb02046.x.
To determine whether a 5-day course of oral prednisolone is superior to a 3-day course in reducing the 2-week morbidity of children with asthma exacerbations who are not hospitalised.
DESIGN, SETTING AND PARTICIPANTS: Double-blind randomised controlled trial of asthma outcomes following a 5-day course of oral prednisolone (1 mg/kg) compared with a 3-day course of prednisolone plus placebo for 2 days. Participants were children aged 2-15 years who presented to the emergency departments of three Queensland hospitals between March 2004 and February 2007 with an acute exacerbation of asthma, but were not hospitalised. Sample size was defined a priori for a study power of 90%.
Difference in proportion of children who were symptom-free at Day 7, as measured by intention-to-treat (ITT) and per-protocol analysis; quality of life (QOL) on Days 7 and 14.
201 children were enrolled, and there was an 82% completion rate. There was no difference between groups in the proportion of children who were symptom-free (observed difference, 0.04 [95% CI, - 0.09 to 0.18] by ITT analysis; 0.04 [95% CI, - 0.17 to 0.09] by per-protocol analysis). There was also no difference between groups in QOL (P = 0.42). The difference between groups for the primary outcome was within the equivalence range calculated post priori.
A 5-day course of oral prednisolone confers no advantage over a 3-day course for children with asthma exacerbations who are not hospitalised.
Australian Clinical Trials Registry ACTRN012605000305628.
确定对于未住院的哮喘急性发作儿童,5天疗程的口服泼尼松龙在降低2周发病率方面是否优于3天疗程。
设计、地点和参与者:一项双盲随机对照试验,比较口服泼尼松龙(1毫克/千克)5天疗程与泼尼松龙3天疗程加2天安慰剂对哮喘结局的影响。参与者为2004年3月至2007年2月间因哮喘急性发作到昆士兰三家医院急诊科就诊但未住院的2至15岁儿童。样本量根据90%的研究效能预先确定。
按意向性分析(ITT)和符合方案分析衡量,第7天无症状儿童比例的差异;第7天和第14天的生活质量(QOL)。
共纳入201名儿童,完成率为82%。两组间无症状儿童比例无差异(ITT分析观察到的差异为0.04[95%可信区间,-0.09至0.18];符合方案分析为0.04[95%可信区间,-0.17至0.09])。两组间生活质量也无差异(P = 0.42)。主要结局的组间差异在事后计算的等效范围内。
对于未住院的哮喘急性发作儿童,5天疗程的口服泼尼松龙并不比3天疗程更具优势。
澳大利亚临床试验注册中心ACTRN012605000305628 。